<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04282200</url>
  </required_header>
  <id_info>
    <org_study_id>2019-0283</org_study_id>
    <nct_id>NCT04282200</nct_id>
  </id_info>
  <brief_title>Ketorolac in Acute Pancreatitis</brief_title>
  <official_title>The Use of Intravenous Ketorolac in a Multimodal Approach to Pain Management in Acute Pancreatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare pain management strategies for patients hospitalized with acute&#xD;
      pancreatitis. Standard of care pain management will be compared to standard of care plus&#xD;
      intravenous ketorolac.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients hospitalized for acute pancreatitis and admitted to an internal medicine team will&#xD;
      be eligible for study. Patients enrolled will be blindly randomized to receive open-label&#xD;
      pain management of standard of care or standard of care plus intravenous ketorolac. Patients&#xD;
      will be enrolled between hour 24 and 48 of hospitalization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">February 24, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Opioid use during study enrollment</measure>
    <time_frame>day 1 to day 5 of study</time_frame>
    <description>oral morphine equivalents (OME)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Day-to-day oral morphine equivalents</measure>
    <time_frame>day 1 to day 5 of study</time_frame>
    <description>Compare opioid use in each day of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of intravenous opioid use</measure>
    <time_frame>During hospital admission</time_frame>
    <description>compare duration of need for IV opioids and transition to oral opioids</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients receiving standard of care pain management including opioids.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketorolac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive standard of care pain management plus intravenous ketorolac.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>intravenous ketorolac 30 mg every 6 hours</description>
    <arm_group_label>Ketorolac</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years old&#xD;
&#xD;
          -  opioid order for pain secondary to acute pancreatitis&#xD;
&#xD;
          -  diagnosis of acute pancreatitis defined by the presence of two of the following three&#xD;
             criteria: abdominal pain, lipase &gt; 3x upper limit of normal, and/or findings of AP on&#xD;
             imaging&#xD;
&#xD;
          -  a patient with acute-on-chronic pancreatitis that does not exhibit elevated lipase&#xD;
             levels is eligible for inclusion if the patient has the other two criteria&#xD;
&#xD;
          -  received at least 3 L of IV crystalloid fluid within first 24 hours of admission to&#xD;
             ensure patients have received initial volume expansion&#xD;
&#xD;
          -  hemodynamically stable represented by a mean arterial blood pressure (MAP) of â‰¥65 mmHg&#xD;
&#xD;
          -  female patients not documented in chart as post-menopause must have a negative&#xD;
             pregnancy test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of chronic heart failure&#xD;
&#xD;
          -  history of acute coronary syndrome (ST-elevation myocardial infarction (STEMI) or&#xD;
             non-ST elevation myocardial infarction (NSTEMI)) within last 6 months&#xD;
&#xD;
          -  history of ischemic or hemorrhagic stroke within last 6 months&#xD;
&#xD;
          -  history of upper gastrointestinal bleed (GI) within last 6 months&#xD;
&#xD;
          -  history of inflammatory bowel disease&#xD;
&#xD;
          -  history of cirrhosis&#xD;
&#xD;
          -  any overt, active bleeding requiring blood transfusion&#xD;
&#xD;
          -  considered to be high bleed risk (platelet &lt; 50,000/mcL)&#xD;
&#xD;
          -  pregnant or breastfeeding&#xD;
&#xD;
          -  prisoners&#xD;
&#xD;
          -  cognitively impaired patients: not alert and oriented to person, place, and time&#xD;
             (patient must be able to consent)&#xD;
&#xD;
          -  allergy to NSAIDs, ketorolac, or aspirin&#xD;
&#xD;
          -  admission to an intensive care unit&#xD;
&#xD;
          -  evidence of infected pancreatitis (i.e. abscess) on imaging studies&#xD;
&#xD;
          -  acute kidney injury or chronic kidney disease with CrCl&lt;30&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony J Gentene, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>February 18, 2020</study_first_submitted>
  <study_first_submitted_qc>February 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2020</study_first_posted>
  <last_update_submitted>December 4, 2020</last_update_submitted>
  <last_update_submitted_qc>December 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Anthony Gentene</investigator_full_name>
    <investigator_title>Clinical Pharmacy Specialist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

